Plain Old Balloon Angioplasty (POBA): Clinical Overview
POBA remains a viable interventional option primarily for coronary lesions when stenting is contraindicated or for peripheral arterial disease, though it has largely been superseded by stenting in most coronary applications due to higher restenosis rates.
Indications
Coronary Applications
Primary indications for POBA in coronary disease:
- Patients requiring urgent noncardiac surgery within 2-6 weeks where dual antiplatelet therapy (DAPT) duration would be problematic with stenting 1
- Lesions where stenting is contraindicated due to high bleeding risk or inability to tolerate prolonged DAPT
- Facilitating subsequent intervention when definitive treatment must be delayed 2
- Selected STEMI cases where balloon angioplasty without stent placement may be appropriate, with P2Y12 inhibitor therapy managed similarly to bare-metal stents 3
Peripheral Applications
- Critical limb ischemia with infrapopliteal disease, particularly in elderly, diabetic, and dialysis-dependent patients 4
- Tibial arterial disease where stent limitations make balloon angioplasty the preferred approach 4, 5
Procedural Technique
Timing Considerations for Subsequent Surgery
Critical timing windows after POBA:
- Minimum delay: 2-4 weeks before elective noncardiac surgery to allow vessel healing at the balloon treatment site 2, 1
- Optimal window: 2-8 weeks after POBA, as delaying beyond 8 weeks increases restenosis risk (30-50%) and theoretically increases perioperative ischemia risk 2, 1
- Avoid surgery within first 2 weeks due to risk of arterial recoil or acute thrombosis 1
Technical Approach
For neurovascular POBA/stenting (extrapolatable principles):
- Achieve activated clotting time (ACT) of 300-350 seconds during procedure with heparin boluses 6
- Initial heparin bolus: 100 units/kg, with hourly ACT monitoring and supplemental dosing 6
Antiplatelet Therapy Recommendations
Coronary POBA
Aspirin monotherapy is the cornerstone:
- Continue aspirin indefinitely at 81 mg daily (preferred maintenance dose) 3
- Do not routinely discontinue aspirin perioperatively - the risk of stopping aspirin outweighs bleeding risk in most surgeries 2, 1
- No routine P2Y12 inhibitor required after the initial healing period, unlike with stenting 2
Peripheral POBA (Tibial/Infrapopliteal)
DAPT regimen for peripheral interventions:
- Pre-procedure: Aspirin plus ticlopidine (or clopidogrel) for 3 days before to allow ticlopidine to achieve full activity 6
- Post-procedure: Continue aspirin (325 mg daily) plus ticlopidine (250 mg twice daily) or clopidogrel (75 mg daily) for at least 4 weeks until endothelialization is complete 6
Perioperative Management
For minor procedures (dental, dermatologic, ophthalmologic):
- Continue aspirin throughout the procedure 7
- If on DAPT, continue aspirin and interrupt P2Y12 inhibitor 7
For major surgery:
- Continue aspirin if possible - weigh bleeding risk against thrombotic risk 2, 1
- No bridging therapy recommended with glycoprotein IIb/IIIa inhibitors, cangrelor, or LMWH 7, 8
Key Clinical Pitfalls
Restenosis Risk
POBA has significantly higher restenosis rates (30-50%) compared to stenting 9. This is the primary limitation and explains why stenting has become dominant in coronary interventions. However, restenotic lesions are usually not life-threatening and can be managed with repeat PCI 1.
Timing Errors
Common mistake: Performing noncardiac surgery too soon (<2 weeks) risks acute thrombosis, while delaying too long (>8 weeks) increases restenosis-related complications 2, 1.
Inappropriate Stent Avoidance
While POBA avoids DAPT requirements, do not use POBA simply to avoid antiplatelet therapy in patients who would otherwise benefit from stenting. The decision should be based on surgical timing, bleeding risk, and ability to comply with DAPT 1.
Antiplatelet Discontinuation
Never stop aspirin without compelling reason in patients post-POBA. The increased thrombotic risk typically outweighs bleeding concerns, even in most surgical contexts 2, 1.
Comparative Outcomes
Success rates: POBA achieves technical success (<30% residual stenosis) in most cases but is limited by high restenosis 4. In peripheral disease, drug-coated balloons demonstrate superior target lesion revascularization rates compared to plain balloons (80 vs 204 per 1000 lesions at one year) 10, though clinical endpoints like amputation and mortality show no difference.
Pediatric applications: In young children with Kawasaki disease coronary stenosis, POBA can be safely performed if calcification is minimal, with good results and minimal restenosis for several years 11.